198 related articles for article (PubMed ID: 36840626)
21. Clinicopathologic and genetic analysis of siblings with NF1 and adult-onset gliomas.
Hariharan S; Donahue JE; Garre C; Origone P; Grewal RP
J Neurol Sci; 2006 Aug; 247(1):105-8. PubMed ID: 16725158
[TBL] [Abstract][Full Text] [Related]
22. Clinical Presentation and Outcome of Patients With Optic Pathway Glioma.
Robert-Boire V; Rosca L; Samson Y; Ospina LH; Perreault S
Pediatr Neurol; 2017 Oct; 75():55-60. PubMed ID: 28847625
[TBL] [Abstract][Full Text] [Related]
23. Alternative lengthening of telomeres, ATRX loss and H3-K27M mutations in histologically defined pilocytic astrocytoma with anaplasia.
Rodriguez FJ; Brosnan-Cashman JA; Allen SJ; Vizcaino MA; Giannini C; Camelo-Piragua S; Webb M; Matsushita M; Wadhwani N; Tabbarah A; Hamideh D; Jiang L; Chen L; Arvanitis LD; Alnajar HH; Barber JR; Rodríguez-Velasco A; Orr B; Heaphy CM
Brain Pathol; 2019 Jan; 29(1):126-140. PubMed ID: 30192422
[TBL] [Abstract][Full Text] [Related]
24. The role of surgical biopsy in the diagnosis of glioma in individuals with neurofibromatosis-1.
Leonard JR; Perry A; Rubin JB; King AA; Chicoine MR; Gutmann DH
Neurology; 2006 Oct; 67(8):1509-12. PubMed ID: 17060590
[TBL] [Abstract][Full Text] [Related]
25. Cerebrospinal fluid proteomic analysis reveals dysregulation of methionine aminopeptidase-2 expression in human and mouse neurofibromatosis 1-associated glioma.
Dasgupta B; Yi Y; Hegedus B; Weber JD; Gutmann DH
Cancer Res; 2005 Nov; 65(21):9843-50. PubMed ID: 16267007
[TBL] [Abstract][Full Text] [Related]
26. Characteristics of H3 K27M-mutant gliomas in adults.
Meyronet D; Esteban-Mader M; Bonnet C; Joly MO; Uro-Coste E; Amiel-Benouaich A; Forest F; Rousselot-Denis C; Burel-Vandenbos F; Bourg V; Guyotat J; Fenouil T; Jouvet A; Honnorat J; Ducray F
Neuro Oncol; 2017 Aug; 19(8):1127-1134. PubMed ID: 28201752
[TBL] [Abstract][Full Text] [Related]
27. Optic Pathway Gliomas in Neurofibromatosis Type 1.
Campen CJ; Gutmann DH
J Child Neurol; 2018 Jan; 33(1):73-81. PubMed ID: 29246098
[TBL] [Abstract][Full Text] [Related]
28. Significance of H3K27M mutation with specific histomorphological features and associated molecular alterations in pediatric high-grade glial tumors.
Bozkurt SU; Dagcinar A; Tanrikulu B; Comunoglu N; Meydan BC; Ozek M; Oz B
Childs Nerv Syst; 2018 Jan; 34(1):107-116. PubMed ID: 29063957
[TBL] [Abstract][Full Text] [Related]
29. [Prognostic significance of combined TERT and IDH gene mutation analysis in diffusely infiltrating gliomas].
Liu QQ; Yin XX; Zou Y; Yu TP; Gong J; Chen XQ; Nie L; Xu M; Zhang MN; Zhou Q; Chen N
Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):658-663. PubMed ID: 30220117
[No Abstract] [Full Text] [Related]
30. [Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].
Li HN; Shan CG; Fan CZ; Cheng LN; Wu SG; Liu MT; Jiang GY; Li Z
Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):192-198. PubMed ID: 30831644
[No Abstract] [Full Text] [Related]
31. Optic pathway-hypothalamic glioma hemorrhage: a series of 9 patients and review of the literature.
van Baarsen K; Roth J; Serova N; Packer RJ; Shofty B; Thomale UW; Cinalli G; Toledano H; Michowiz S; Constantini S
J Neurosurg; 2018 Dec; 129(6):1407-1415. PubMed ID: 29424646
[TBL] [Abstract][Full Text] [Related]
32. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
33. Global microRNA profiling identified miR-10b-5p as a regulator of neurofibromatosis 1 (NF1)-glioma migration.
Nix JS; Yuan M; Imada EL; Ames H; Marchionni L; Gutmann DH; Rodriguez FJ
Neuropathol Appl Neurobiol; 2021 Feb; 47(1):96-107. PubMed ID: 32603552
[TBL] [Abstract][Full Text] [Related]
34. Characterization of gliomas: from morphology to molecules.
Ferris SP; Hofmann JW; Solomon DA; Perry A
Virchows Arch; 2017 Aug; 471(2):257-269. PubMed ID: 28674742
[TBL] [Abstract][Full Text] [Related]
35. Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments.
Amato A; Imbimbo BP; Falsini B
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5636-5653. PubMed ID: 37401302
[TBL] [Abstract][Full Text] [Related]
36. The genetic landscape of gliomas arising after therapeutic radiation.
López GY; Van Ziffle J; Onodera C; Grenert JP; Yeh I; Bastian BC; Clarke J; Oberheim Bush NA; Taylor J; Chang S; Butowski N; Banerjee A; Mueller S; Kline C; Torkildson J; Samuel D; Siongco A; Raffel C; Gupta N; Kunwar S; Mummaneni P; Aghi M; Theodosopoulos P; Berger M; Phillips JJ; Pekmezci M; Tihan T; Bollen AW; Perry A; Solomon DA
Acta Neuropathol; 2019 Jan; 137(1):139-150. PubMed ID: 30196423
[TBL] [Abstract][Full Text] [Related]
37. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
Fangusaro J; Onar-Thomas A; Young Poussaint T; Wu S; Ligon AH; Lindeman N; Banerjee A; Packer RJ; Kilburn LB; Goldman S; Pollack IF; Qaddoumi I; Jakacki RI; Fisher PG; Dhall G; Baxter P; Kreissman SG; Stewart CF; Jones DTW; Pfister SM; Vezina G; Stern JS; Panigrahy A; Patay Z; Tamrazi B; Jones JY; Haque SS; Enterline DS; Cha S; Fisher MJ; Doyle LA; Smith M; Dunkel IJ; Fouladi M
Lancet Oncol; 2019 Jul; 20(7):1011-1022. PubMed ID: 31151904
[TBL] [Abstract][Full Text] [Related]
38. Pediatric Diffuse Midline Gliomas H3 K27M-Mutant and Non-Histone Mutant Midline High-Grade Gliomas in Neurofibromatosis Type 1 in Comparison With Non-Syndromic Children: A Single-Center Pilot Study.
Garibotto F; Madia F; Milanaccio C; Verrico A; Piccardo A; Tortora D; Piatelli G; Diana MC; Capra V; Garrè ML; Rossi A; Morana G
Front Oncol; 2020; 10():795. PubMed ID: 32582540
[No Abstract] [Full Text] [Related]
39. Neurofibromatosis type 1 associated low grade gliomas: A comparison with sporadic low grade gliomas.
Helfferich J; Nijmeijer R; Brouwer OF; Boon M; Fock A; Hoving EW; Meijer L; den Dunnen WF; de Bont ES
Crit Rev Oncol Hematol; 2016 Aug; 104():30-41. PubMed ID: 27263935
[TBL] [Abstract][Full Text] [Related]
40. Prolonged survival in adult neurofibromatosis type I patients with recurrent high-grade gliomas treated with bevacizumab.
Theeler BJ; Ellezam B; Yust-Katz S; Slopis JM; Loghin ME; de Groot JF
J Neurol; 2014 Aug; 261(8):1559-64. PubMed ID: 24859329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
